End Points for Comparative Effectiveness Research in Heart Failure

Heart Failure Clinics

Volumn 9, Issue 1, 2013, Pages 15-28

  Allen, Larry A ^a   Spertus, John A ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Comparative effectiveness research; Congestive heart failure; End points; Study design

Indexed keywords

CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; PATIENT SAFETY; QUALITY OF LIFE; REVIEW; SUDDEN DEATH; SURVIVAL; TREATMENT OUTCOME;

COMPARATIVE EFFECTIVENESS RESEARCH; COST SAVINGS; HEALTH STATUS; HEART FAILURE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT CARE MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS; RESEARCH DESIGN; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84869493633     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.09.002     Document Type: Review

References (69)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):e391-e479.
2. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29(19):2388-2442.
3. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010, 16(6):e1-e194.
4. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(6):e240.
5. Allen L.A., O'Connor C.M. Management of acute decompensated heart failure. CMAJ 2007, 176(6):797-805.
6. Paulus W.J., van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 2010, 55(6):526-537.
7. Goodlin S.J., Hauptman P.J., Arnold R., et al. Consensus statement: palliative and supportive care in advanced heart failure. J Card Fail 2004, 10(3):200-209.
8. Stewart S., MacIntyre K., Hole D.J., et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3(3):315-322.
9. Yusuf S., Negassa A. Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes?. Am Heart J 2002, 143(1):22-28.
10. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351(24):2481-2488.
11. O'Connor C.M., Miller A.H., Konstam M.A., et al. Mode of death and cardiovascular re-hospitalization in patients admitted with acute heart failure-results from the EVEREST program. Eur Heart J 2008, (Suppl 1):59-60.
12. Carson P., Anand I., O'Connor C., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005, 46(12):2329-2334.
13. Solomon S.D., Anavekar N., Skali H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005, 112(24):3738-3744.
14. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121(12):1393-1405.
15. Mahaffey K.W., Harrington R.A., Akkerhuis M., et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2001, 2(4):180-186.
16. Fox C.S., Evans J.C., Larson M.G., et al. A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death. Am J Cardiol 2005, 95(7):856-859.
17. Lewis E.F., Johnson P.A., Johnson W., et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001, 20(9):1016-1024.
18. Stevenson L.W., Hellkamp A.S., Leier C.V., et al. Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008, 52(21):1702-1708.
19. Stewart G.C., Brooks K., Pratibhu P.P., et al. Thresholds of physical activity and life expectancy for patients considering destination ventricular assist devices. J Heart Lung Transplant 2009, 28(9):863-869.
20. Spertus J.A. Evolving applications for patient-centered health status measures. Circulation 2008, 118(20):2103-2110.
21. The Criteria Committee of the New York Heart Association Nomenclature and criteria for diagnosis of diseases of the heart and blood vessels 1964, Little Brown, Boston.
22. Rafeal C., Briscoe C., Davies J., et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 2007, 93(4):476-482.
23. Bennett J.A., Riegel B., Bittner V., et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 2002, 31(4):262-270.
24. Allen L.A., Hernandez A.F., O'Connor C.M., et al. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009, 53(24):2248-2258.
25. Pang P.S., Cleland J.G., Teerlink J.R., et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008, 29(6):816-824.
26. Mahler D.A., Weinberg D.H., Wells C.K., et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85(6):751-758.
27. Mahler D.A., Rosiello R.A., Harver A., et al. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 1987, 135(6):1229-1233.
28. Allen L.A., Metra M., Milo-Cotter O., et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 2008, 14(9):777-784.
29. Rector T.S., Kubo S.H., Cohn J.N. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993, 71(12):1106-1107.
30. Green C.P., Porter C.B., Bresnahan D.R., et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000, 35(5):1245-1255.
31. Spertus J., Peterson E., Conard M.W., et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005, 150(4):707-715.
32. Soto G.E., Jones P., Weintraub W.S., et al. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 2004, 110(5):546-551.
33. Kosiborod M., Soto G.E., Jones P.G., et al. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation 2007, 115(15):1975-1981.
34. Heidenreich P.A., Spertus J.A., Jones P.G., et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 2006, 47(4):752-756.
35. Chan P.S., Soto G., Jones P.G., et al. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 2009, 119(3):398-407.
36. Zuluaga M.C., Guallar-Castillon P., Lopez-Garcia E., et al. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur J Heart Fail 2010, 12(12):1372-1378.
37. The EQ-5D: An Instrument Designed to Describe and Value Health. Available at: Accessed December 18, 2010. http://www.euroqol.org/.
38. Utility Assessment of Health Related Quality of Life. Available at: Accessed December 18, 2010. http://www.healthutilities.com/.
39. Hlatky M.A., Boineau E.R., Higgenbotham M.B., et al. A brief self-administered questionnaire to determine function capacity (The Duke Activity Status Index). Am J Cardiol 1989, 64:651-654.
40. The Short Form 36. Available at: Accessed December 18, 2010. http://www.sf-36.org/.
41. Spertus J.A., Tooley J., Jones P., et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J 2002, 143(4):636-642.
42. Von Neumann J., Morgenstern O. Theory of games and economic behavior 1944, Princeton University Press, Princeton (NJ). 1st edition.
43. Torrance G.W., Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989, 5(4):559-575.
44. Torrance G.W. Utility approach to measuring health-related quality of life. J Chronic Dis 1987, 40(6):593-603.
45. Porter M.E. What is value in health care?. N Engl J Med 2010, 363(26):2477-2481.
46. Pearson S.D., Rawlins M.D. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005, 294(20):2618-2622.
47. Weinstein M.C., Skinner J.A. Comparative effectiveness and health care spending-implications for reform. N Engl J Med 2010, 362(5):460-465.
48. Liao L., Allen L.A., Whellan D.J. Economic burden of heart failure in the elderly. Pharmacoeconomics 2008, 26(6):447-462.
49. Blair J.E., Zannad F., Konstam M.A., et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008, 52(20):1640-1648.
50. Piaggio G., Elbourne D.R., Altman D.G., et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006, 295(10):1152-1160.
51. Reed S.D., Anstrom K.J., Seils D.M., et al. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff 2008, 27(5):w360-w370.
52. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8(4):431-440.
53. Bucher H.C., Guyatt G.H., Cook D.J., et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999, 282(8):771-778.
54. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293(15):1900-1905.
55. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
56. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
57. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358(14):1431-1443.
58. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21):2109-2122.
59. Jones R.H., Velazquez E.J., Michler R.E., et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009, 360(17):1705-1717.
60. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287(12):1531-1540.
61. Hernandez A.F., O'Connor C.M., Starling R.C., et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009, 157(2):271-277.
62. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297(17):1883-1891.
63. Packer M. Randomized multicenter evaluation of intravenous levosimendan efficacy versus placebo in the short-term treatment of decompensated heart failure study (REVIVE-2). Paper presented at: Proceedings of the American Heart Association Scientific Sessions, Dallas, November 13-16, 2005.
64. Ronco C., Haapio M., House A.A., et al. Cardiorenal syndrome. J Am Coll Cardiol 2008, 52(19):1527-1539.
65. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010, 363(15):1419-1428.
66. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005, 294(13):1625-1633.
67. Felker G.M., Anstrom K.J., Rogers J.G. A global ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail 2008, 14(5):368-372.
68. Felker G.M., Maisel A.S. Development of therapeutics for heart failure: a global rank end point for clinical trials of acute heart failure. Circ Heart Fail 2010, 3:643-646.
69. Ferreira-Gonzalez I., Busse J.W., Heels-Ansdell D., et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007, 334(7597):786.